Sriram Ryali
CIK 1762893 · Chief Financial Officer · last filed 2026-02-20
Sriram Ryali is a Chief Financial Officer who has filed 15 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for CRBU, was dated Feb 20, 2026. Across all open-market trades the lifetime net is +$45.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $537.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$537.3K
3
15
$45.7K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRBU | Chief Financial Officer | 72,360 | $1.59 | $115.4K | $24.7K | 3 | 2026-02-20 |
| CDXS | Chief Financial Officer | 175,791 | $2.40 | $421.9K | $19.9K | 3 | 2024-01-02 |
| Eiger BioPharmaceuticals, Inc. (EIGR) Delisted | Chief Financial Officer | 41,566 | $1.73 | $71.7K | $1.2K | 9 | 2022-03-14 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-20 | CRBU | Grant (A) | +55,000 | $0 | EDGAR |
| 2025-01-30 | CRBU | Buy (P) | +17,360 | $24.7K | EDGAR |
| 2025-01-10 | CRBU | Grant (A) | — | $0 | EDGAR |
| 2024-01-02 | CDXS | Grant (A) | +52,350 | $0 | EDGAR |
| 2023-09-12 | CDXS | Buy (P) | +11,650 | $19.9K | EDGAR |
| 2023-02-14 | CDXS | Grant (A) | +111,791 | $0 | EDGAR |
| 2022-03-14 | Eiger BioPharmaceuticals, Inc. (EIGR) Delisted | Sell (S) | −2,266 | -$12.7K | EDGAR |
| 2022-03-11 | Eiger BioPharmaceuticals, Inc. (EIGR) Delisted | Grant (A) | +24,000 | $0 | EDGAR |
| 2021-07-30 | Eiger BioPharmaceuticals, Inc. (EIGR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-11 | Eiger BioPharmaceuticals, Inc. (EIGR) Delisted | Grant (A) | — | $0 | EDGAR |